{"id":"W2738541296","doi":"10.1016/s0140-6736(17)31917-7","title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":504,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada); Ottawa Hospital","funders":"Bristol-Myers Squibb","keywords":"Rilpivirine; Abacavir; Medicine; Lamivudine; Tolerability; Emtricitabine; Dosing; Internal medicine; Pharmacology; Adverse effect; Viral load; Virology; Human immunodeficiency virus (HIV)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001069631,0.0002120583,0.0008416797,0.00007240786,0.0002232144,0.00009989959,0.0002119245,0.00007272747,0.00001305178],"category_scores_gemma":[0.0003236546,0.0001260663,0.00003559738,0.0001096817,0.00015174,0.0002157304,0.0001294169,0.0002681939,0.00000860176],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005726747,"about_ca_system_score_gemma":0.0001137251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001172329,"about_ca_topic_score_gemma":0.001297678,"domain_scores_codex":[0.998695,0.00009924948,0.0004058035,0.0003075472,0.0002147079,0.0002776785],"domain_scores_gemma":[0.9986315,0.0001328463,0.000352013,0.0007276412,0.00006950385,0.00008647907],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8831934,0.00226687,0.07377625,0.0002752734,0.0004156103,0.0003274592,0.002641022,0.000003837921,0.0004642998,0.00002460924,0.001020272,0.03559105],"study_design_scores_gemma":[0.9172025,0.001373475,0.07660567,0.0009519946,0.000208047,0.00003841289,0.00008210133,0.0003414893,0.001459233,0.00002523659,0.001528281,0.0001836023],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911796,0.00005795633,0.00009517209,0.003701448,0.0001046384,0.002289188,0.00003037859,0.00002289655,0.002518659],"genre_scores_gemma":[0.9975559,0.0002451992,0.0007652918,0.00005473284,0.0003659149,0.0001209136,0.00007029696,0.00001890301,0.0008029106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03540745,"threshold_uncertainty_score":0.5140836,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04306374395930505,"score_gpt":0.3384009476299573,"score_spread":0.2953372036706522,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}